A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR)
This study is testing a new experimental cancer medicine called neladalkib to see if it works better than a standard medicine called alectinib. The goal is to help people with a specific type of advanced lung cancer live longer without their cancer growing.
You might be able to join if you have advanced non-small cell lung cancer with a specific genetic change called ALK. You must not have received prior full-body treatments for this advanced lung cancer. People who have already taken an ALK-blocking pill such as alectinib, even after surgery, cannot join.
Participants will be randomly chosen to receive either the new experimental drug or the standard medication. Your health and tumor growth will be closely monitored with regular check-ups and scans.
This study is currently recruiting participants at multiple locations, including sites in Arizona and California. Your study doctor will provide all the details about what to expect at your local clinic. It is recruiting at 158 locations in 29 countries, including 22 in the United States and 1 in Canada (Toronto).
- 1Testing a new targeted cancer drug called neladalkib
- 2Comparing the new drug against a standard treatment, alectinib
- 3Open to patients with ALK-positive advanced lung cancer who have not yet had whole-body treatment
Related video
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.